Home
Home » companies

Exelixis

The Worst-Performing Biotechs in 2012 and 1 to Avoid in 2013

The Worst-Performing Biotechs in 2012 and 1 to Avoid in 2013
Motley Fool

The Road Toward Far-Reaching Therapeutics Through Illumina, Sarepta

The Road Toward Far-Reaching Therapeutics Through Illumina, Sarepta
Seeking Alpha

Exelixis' Crowning Achievement

Exelixis' Crowning Achievement
Motley Fool

Exelixis Wins First Approval of Cancer Drug

Exelixis Wins First Approval of Cancer Drug
Minyanville

Exelixis Traders Brace For Upcoming FDA Decision

Exelixis Traders Brace For Upcoming FDA Decision
Seeking Alpha

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges
Seeking Alpha

Exelixis, Celgene, Gilead Sciences, Dynavax See Key Dates in November

Exelixis, Celgene, Gilead Sciences, Dynavax See Key Dates in November
Minyanville

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?

ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?
Seeking Alpha

Exelixis: First Partnered Program Enters Phase III

Exelixis: First Partnered Program Enters Phase III
Seeking Alpha

Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012

Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012
Yahoo/BusinessWire